Wounds-Pipeline Review, H1 2015

Wounds-Pipeline Review, H1 2015

  • Products Id :- GMDHC6573IDB
  • |
  • Pages: 254
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Wounds-Pipeline Review, H1 2015


Global Markets Direct's, 'Wounds-Pipeline Review, H1 2015', provides an overview of the Wounds's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Wounds

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Wounds

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Wounds Overview 11

Therapeutics Development 12

Pipeline Products for Wounds-Overview 12

Pipeline Products for Wounds-Comparative Analysis 13

Wounds-Therapeutics under Development by Companies 14

Wounds-Therapeutics under Investigation by Universities/Institutes 20

Wounds-Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Wounds-Products under Development by Companies 26

Wounds-Products under Investigation by Universities/Institutes 32

Wounds-Companies Involved in Therapeutics Development 34

Advancell 34

Aerpio Therapeutics, Inc. 35

Agenta Biotechnologies, Inc. 36

AlgiPharma AS 37

AndroScience Corporation 38

AnGes MG, Inc. 39

APEIRON Biologics AG 40

Aridis Pharmaceuticals LLC 41

Beech Tree Labs, Inc. 42

Bio3 Research S.r.l 43

Biokine Therapeutics Ltd. 44

Biotec Pharmacon ASA 45

Birken AG 46

Blueberry Therapeutics Ltd 47

Caladrius Biosciences, Inc. 48

Cellphire, Inc. 49

CorMedix, Inc. 50

CYATHUS EXQUIRERE PharmaforschungsGmbH 51

Destiny Pharma Limited 52

FibroGen, Inc. 53

Foresee Pharmaceuticals, LLC 54

GangaGen Inc. 55

Garnet BioTherapeutics 56

Gene Signal International SA 57

GlaxoSmithKline Plc 58

HanAll Biopharma Co., Ltd. 59

IntelliCell BioSciences Inc. 60

Juventas Therapeutics, Inc. 61

Kasiak Research Pvt. Ltd. 62

Kuros Biosurgery AG 63

LegoChem Biosciences, Inc 64

Living Cell Technologies Limited 65

MediWound Ltd. 66

miRagen Therapeutics, Inc. 67

Molecular Design International, Inc. 68

Nabriva Therapeutics AG 69

NatureWise Biotech & Medicals Corporation 70

Neumedicines Inc. 71

Novan, Inc. 72

Nuvo Research Inc. 73

Octapharma AG 74

Omeros Corporation 75

Omnio Healer AB 76

Pacific Northwest Biotechnology, LLC 77

Pergamum AB 78

Pherecydes Pharma SA 79

Regenics AS 80

RXi Pharmaceuticals Corporation 81

Sanofi 82

SomaGenics Inc. 83

Stratatech Corporation 84

Sucampo Pharmaceuticals, Inc. 85

Symic Biomedical, Inc. 86

Thesan Pharmaceuticals, Inc. 87

VBS Pharmaceuticals 88

Vida Therapeutics Inc. 89

Wounds-Therapeutics Assessment 90

Assessment by Monotherapy Products 90

Assessment by Target 91

Assessment by Mechanism of Action 94

Assessment by Route of Administration 97

Assessment by Molecule Type 99

Drug Profiles 101

A-3APO-Drug Profile 101

Adipose Stem Cell Therapy for Skin Wound-Drug Profile 103

AG-30/5C-Drug Profile 104

AKB-4924-Drug Profile 105

ALLO-ASC-Drug Profile 106

ANs-31-Drug Profile 107

APN-201-Drug Profile 108

APO-2-Drug Profile 110

Arginine Butyrate-Drug Profile 111

ARN-077-Drug Profile 112

ASCJ-9-Drug Profile 113

Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound-Drug Profile 115

Autologous Vascular Cells Therapy-Drug Profile 116

BB-1000-Drug Profile 117

BC-7013-Drug Profile 118

Biosimilar for Diabetic Wounds-Drug Profile 119

BKT-170-Drug Profile 120

BTL-slo-Drug Profile 121

CAR Peptide-Drug Profile 122

CaTx-II-Drug Profile 123

Cell Therapy for Wounds-Drug Profile 124

CM-101-Drug Profile 125

cobiprostone-Drug Profile 127

CR-2016-Drug Profile 128

CRMD-004-Drug Profile 129

CTR-2-Drug Profile 130

Cyathus-1102-B-Drug Profile 131

daprodustat-Drug Profile 132

DB-2121-Drug Profile 134

Drug for Dermatology and Infectious Diseases-Drug Profile 135

Drug to Antagonize Beta 2 Receptor for Wound Healing-Drug Profile 136

Drugs to Activate iRhom2 for Wound Healing and Cancer-Drug Profile 137

Drugs to Agonize c-Met for Wound-Drug Profile 138

Drugs to Inhibit 11beta-HSD1 for Wound Healing-Drug Profile 139

EscharEx-Drug Profile 140

FG-6874-Drug Profile 141

FP-009-Drug Profile 142

G-10-Drug Profile 143

GBT-009-Drug Profile 144

Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers-Drug Profile 146

GS-156-Drug Profile 147

HL-156FIB-Drug Profile 148

Human Growth Factor-Drug Profile 149

hVGF-Drug Profile 150

JM-2-Drug Profile 151

JVS-100-Drug Profile 152

KL-7016-Drug Profile 154

KUR-213-Drug Profile 155

LCB-030110-Drug Profile 156

LWnt-3a-Drug Profile 157

MDI-301-Drug Profile 158

Mesenchymal Cells for Wound Care-Drug Profile 160

MGN-4220-Drug Profile 161

MMP-26051-Drug Profile 162

MMP-26052-Drug Profile 163

Monoclonal Antibody Conjugated for Burns and Wounds-Drug Profile 164

Mul-1867-Drug Profile 165

NBM-67-Drug Profile 166

NMIL-121-Drug Profile 167

NTCELL-Drug Profile 169

OleogelS-10-Drug Profile 171

Oligomer G for Wounds And Burns-Drug Profile 173

Oxofoam-Drug Profile 174

P-128-Drug Profile 175

Panaecin-Drug Profile 176

Peptide for Wounds-Drug Profile 177

perflenapent for wound healing-Drug Profile 178

Perlecan-Drug Profile 179

PGF-Drug Profile 181

plasminogen (recombinant)-Drug Profile 182

Polysaccharide for Wounds and Scars-Drug Profile 183

PP-0121-Drug Profile 184

PP-1131-Drug Profile 186

Protein for Hematological Disorders, Dermatology, Shock and Injury-Drug Profile 188

Protein for Wounds and Diabetic Complications-Drug Profile 189

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders-Drug Profile 190

Protein to Inhibit SEB and TSST-1 for Infectious Disease, Dermatology, Respiratory Disorders and Other Diseases-Drug Profile 191

PXL-181-Drug Profile 192

Recombinant Erythropoetin For Wounds, Bone Regeneration and Ulcers-Drug Profile 193

Recombinant Protein to Activate Fibroblast Growth Factor for Wounds-Drug Profile 194

Recombinant Protein to Inhibit Granzyme B for Cardiovascular and Dermatology Diseases-Drug Profile 195

Refaheal-Drug Profile 196

RNAi Oligonucleotide for Wound Healing-Drug Profile 197

RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing-Drug Profile 198

Small Molecule for Chronic Wounds and Burns-Drug Profile 199

Small Molecule to Inhibit MMP-1 and MMP-13 for Wounds-Drug Profile 200

Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles-Drug Profile 201

Small Molecules for Wounds and Scars-Drug Profile 202

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology-Drug Profile 203

Soluble Beta Glucan-Drug Profile 204

Stem Cell Therapy for Wound Healing-Drug Profile 207

StrataGraft Skin Tissue-Drug Profile 208

Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders-Drug Profile 210

Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology-Drug Profile 212

Thrombosomes-Drug Profile 214

V-2248-Drug Profile 215

Vasculotide-Drug Profile 216

Vernex-Drug Profile 217

XEN-103-Drug Profile 218

XF-70-Drug Profile 219

Wounds-Recent Pipeline Updates 220

Wounds-Dormant Projects 233

Wounds-Discontinued Products 239

Wounds-Product Development Milestones 240

Featured News & Press Releases 240

Appendix 246

Methodology 246

Coverage 246

Secondary Research 246

Primary Research 246

Expert Panel Validation 246

Contact Us 246

Disclaimer 247

List of Tables

Number of Products under Development for Wounds, H1 2015 19

Number of Products under Development for Wounds-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 22

Number of Products under Development by Companies, H1 2015 (Contd..1) 23

Number of Products under Development by Companies, H1 2015 (Contd..2) 24

Number of Products under Development by Companies, H1 2015 (Contd..3) 25

Number of Products under Development by Companies, H1 2015 (Contd..4) 26

Number of Products under Investigation by Universities/Institutes, H1 2015 27

Comparative Analysis by Late Stage Development, H1 2015 29

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Development, H1 2015 31

Comparative Analysis by Unknown Stage Development, H1 2015 32

Products under Development by Companies, H1 2015 33

Products under Development by Companies, H1 2015 (Contd..1) 34

Products under Development by Companies, H1 2015 (Contd..2) 35

Products under Development by Companies, H1 2015 (Contd..3) 36

Products under Development by Companies, H1 2015 (Contd..4) 37

Products under Development by Companies, H1 2015 (Contd..5) 38

Products under Investigation by Universities/Institutes, H1 2015 39

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 40

Wounds-Pipeline by Advancell, H1 2015 41

Wounds-Pipeline by Aerpio Therapeutics, Inc., H1 2015 42

Wounds-Pipeline by Agenta Biotechnologies, Inc., H1 2015 43

Wounds-Pipeline by AlgiPharma AS, H1 2015 44

Wounds-Pipeline by AndroScience Corporation, H1 2015 45

Wounds-Pipeline by AnGes MG, Inc., H1 2015 46

Wounds-Pipeline by APEIRON Biologics AG, H1 2015 47

Wounds-Pipeline by Aridis Pharmaceuticals LLC, H1 2015 48

Wounds-Pipeline by Beech Tree Labs, Inc., H1 2015 49

Wounds-Pipeline by Bio3 Research S.r.l, H1 2015 50

Wounds-Pipeline by Biokine Therapeutics Ltd., H1 2015 51

Wounds-Pipeline by Biotec Pharmacon ASA, H1 2015 52

Wounds-Pipeline by Birken AG, H1 2015 53

Wounds-Pipeline by Blueberry Therapeutics Ltd, H1 2015 54

Wounds-Pipeline by Caladrius Biosciences, Inc. , H1 2015 55

Wounds-Pipeline by Cellphire, Inc., H1 2015 56

Wounds-Pipeline by CorMedix, Inc., H1 2015 57

Wounds-Pipeline by CYATHUS EXQUIRERE PharmaforschungsGmbH, H1 2015 58

Wounds-Pipeline by Destiny Pharma Limited, H1 2015 59

Wounds-Pipeline by FibroGen, Inc., H1 2015 60

Wounds-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 61

Wounds-Pipeline by GangaGen Inc., H1 2015 62

Wounds-Pipeline by Garnet BioTherapeutics, H1 2015 63

Wounds-Pipeline by Gene Signal International SA, H1 2015 64

Wounds-Pipeline by GlaxoSmithKline Plc, H1 2015 65

Wounds-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 66

Wounds-Pipeline by IntelliCell BioSciences Inc., H1 2015 67

Wounds-Pipeline by Juventas Therapeutics, Inc., H1 2015 68

Wounds-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 69

Wounds-Pipeline by Kuros Biosurgery AG, H1 2015 70

Wounds-Pipeline by LegoChem Biosciences, Inc, H1 2015 71

Wounds-Pipeline by Living Cell Technologies Limited, H1 2015 72

Wounds-Pipeline by MediWound Ltd., H1 2015 73

Wounds-Pipeline by miRagen Therapeutics, Inc., H1 2015 74

Wounds-Pipeline by Molecular Design International, Inc., H1 2015 75

Wounds-Pipeline by Nabriva Therapeutics AG, H1 2015 76

Wounds-Pipeline by NatureWise Biotech & Medicals Corporation, H1 2015 77

Wounds-Pipeline by Neumedicines Inc., H1 2015 78

Wounds-Pipeline by Novan, Inc., H1 2015 79

Wounds-Pipeline by Nuvo Research Inc., H1 2015 80

Wounds-Pipeline by Octapharma AG, H1 2015 81

Wounds-Pipeline by Omeros Corporation, H1 2015 82

Wounds-Pipeline by Omnio Healer AB, H1 2015 83

Wounds-Pipeline by Pacific Northwest Biotechnology, LLC, H1 2015 84

Wounds-Pipeline by Pergamum AB, H1 2015 85

Wounds-Pipeline by Pherecydes Pharma SA, H1 2015 86

Wounds-Pipeline by Regenics AS, H1 2015 87

Wounds-Pipeline by RXi Pharmaceuticals Corporation, H1 2015 88

Wounds-Pipeline by Sanofi, H1 2015 89

Wounds-Pipeline by SomaGenics Inc., H1 2015 90

Wounds-Pipeline by Stratatech Corporation, H1 2015 91

Wounds-Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 92

Wounds-Pipeline by Symic Biomedical, Inc., H1 2015 93

Wounds-Pipeline by Thesan Pharmaceuticals, Inc., H1 2015 94

ounds-Pipeline by VBS Pharmaceuticals, H1 2015 95

Wounds-Pipeline by Vida Therapeutics Inc., H1 2015 96

Assessment by Monotherapy Products, H1 2015 97

Number of Products by Stage and Target, H1 2015 99

Number of Products by Stage and Mechanism of Action, H1 2015 102

Number of Products by Stage and Route of Administration, H1 2015 105

Number of Products by Stage and Molecule Type, H1 2015 107

Wounds Therapeutics-Recent Pipeline Updates, H1 2015 227

Wounds-Dormant Projects, H1 2015 240

Wounds-Dormant Projects (Contd..1), H1 2015 241

Wounds-Dormant Projects (Contd..2), H1 2015 242

Wounds-Dormant Projects (Contd..3), H1 2015 243

Wounds-Dormant Projects (Contd..4), H1 2015 244

Wounds-Dormant Projects (Contd..5), H1 2015 245

Wounds-Discontinued Products, H1 2015 246

List of Figures

Number of Products under Development for Wounds, H1 2015 19

Number of Products under Development for Wounds-Comparative Analysis, H1 2015 20

Number of Products under Development by Companies, H1 2015 21

Number of Products under Investigation by Universities/Institutes, H1 2015 27

Comparative Analysis by Late Stage Development, H1 2015 29

Comparative Analysis by Clinical Stage Development, H1 2015 30

Comparative Analysis by Early Stage Products, H1 2015 31

Assessment by Monotherapy Products, H1 2015 97

Number of Products by Top 10 Targets, H1 2015 98

Number of Products by Stage and Top 10 Targets, H1 2015 98

Number of Products by Top 10 Mechanism of Actions, H1 2015 101

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 101

Number of Products by Top 10 Routes of Administration, H1 2015 104

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 104

Number of Products by Top 10 Molecule Types, H1 2015 106

Number of Products by Stage and Top 10 Molecule Types, H1 2015 106

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com


Aerpio Therapeutics, Inc.

Agenta Biotechnologies, Inc.

AlgiPharma AS

AndroScience Corporation

AnGes MG, Inc.

APEIRON Biologics AG

Aridis Pharmaceuticals LLC

Beech Tree Labs, Inc.

Bio3 Research S.r.l

Biokine Therapeutics Ltd.

Biotec Pharmacon ASA

Birken AG

Blueberry Therapeutics Ltd

Caladrius Biosciences, Inc.

Cellphire, Inc.

CorMedix, Inc.

CYATHUS EXQUIRERE PharmaforschungsGmbH

Destiny Pharma Limited

FibroGen, Inc.

Foresee Pharmaceuticals, LLC

GangaGen Inc.

Garnet BioTherapeutics

Gene Signal International SA

GlaxoSmithKline Plc

HanAll Biopharma Co., Ltd.

IntelliCell BioSciences Inc.

Juventas Therapeutics, Inc.

Kasiak Research Pvt. Ltd.

Kuros Biosurgery AG

LegoChem Biosciences, Inc

Living Cell Technologies Limited

MediWound Ltd.

miRagen Therapeutics, Inc.

Molecular Design International, Inc.

Nabriva Therapeutics AG

NatureWise Biotech & Medicals Corporation

Neumedicines Inc.

Novan, Inc.

Nuvo Research Inc.

Octapharma AG

Omeros Corporation

Omnio Healer AB

Pacific Northwest Biotechnology, LLC

Pergamum AB

Pherecydes Pharma SA

Regenics AS

RXi Pharmaceuticals Corporation


SomaGenics Inc.

Stratatech Corporation

Sucampo Pharmaceuticals, Inc.

Symic Biomedical, Inc.

Thesan Pharmaceuticals, Inc.

VBS Pharmaceuticals

Vida Therapeutics Inc.

Wounds Therapeutic Products under Development, Key Players in Wounds Therapeutics, Wounds Pipeline Overview, Wounds Pipeline, Wounds Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com